We are live on
!
Find out more
JJ
Johnson & Johnson Portfolio holdings
AUM
$799M
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter
Est. Return
-21.03%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
–
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
118.56%
Top 10 Holdings %
Top 10 Hldgs %
95.42%
Holding
25
New
25
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$383M |
| 2 |
Fate Therapeutics
FATE
|
+$265M |
| 3 |
Arrowhead Research
ARWR
|
+$211M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$104M |
| 5 |
HLTH
Cue Health Inc. Common Stock
HLTH
|
+$87.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.89% |
| 2 | Technology | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Illumina
ILMN
$29.1B
| $329M | 28.83% |
+832,855
| New | +$383M |
|
|
2
Arrowhead Research
ARWR
$12.1B
| $204M | 17.86% |
+3,260,869
| New | +$211M |
|
|
3
Fate Therapeutics
FATE
$294M
| $200M | 17.57% |
+3,379,064
| New | +$265M |
|
4
Legend Biotech
LEGN
$3.93B
| $82.4M | 7.23% |
+1,629,173
| New | +$67.8M |
|
|
HLTH
5
DELISTED
Cue Health Inc. Common Stock
HLTH
| $65.5M | 5.75% |
+5,548,864
| New | +$87.4M |
|
6
CVRx
CVRX
$78.3M
| $57.8M | 5.07% |
+3,495,575
| New | +$67.1M |
|
|
7
Protagonist Therapeutics
PTGX
$9.8B
| $43.4M | 3.81% |
+2,449,183
| New | +$104M |
|
8
Procept Biorobotics
PRCT
$1.26B
| $38.9M | 3.41% |
+1,018,478
| New | +$39.1M |
|
9
MeiraGTx Holdings
MGTX
$1.17B
| $38.2M | 3.35% |
+2,898,550
| New | +$39.7M |
|
|
FUSN
10
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $29.1M | 2.55% |
+3,670,516
| New | +$30.9M |
|
11
Vor Biopharma
VOR
$1.38B
| $16.9M | 1.48% |
+53,733
| New | +$16M |
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $7.69M | 0.67% |
+1,000,000
| New | +$9.12M |
|
13
BiomX
PHGE
$1.67M
| $6.53M | 0.57% |
+11,228
| New | +$8.7M |
|
14
Adicet Bio
ACET
$77.3M
| $5.71M | 0.5% |
+45,559
| New | +$5.65M |
|
|
PHAS
15
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $5M | 0.44% |
+1,607,044
| New | +$5.36M |
|
|
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $3.48M | 0.31% |
+281,052
| New | +$3.17M |
|
17
Aldeyra Therapeutics
ALDX
$86.9M
| $3.47M | 0.3% |
+394,834
| New | +$3.62M |
|
|
CSLT
18
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $1.27M | 0.11% |
+811,295
| New | +$1.59M |
|
19
Neuropace
NPCE
$498M
| $879K | 0.08% |
+55,435
| New | +$1.16M |
|
|
TCON
20
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $325K | 0.03% |
+4,200
| New | +$356K |
|
21
Gyre Therapeutics
GYRE
$693M
| $275K | 0.02% |
+8,927
| New | +$294K |
|
|
ZY
22
DELISTED
Zymergen Inc. Common Stock
ZY
| $218K | 0.02% |
+16,553
| New | +$351K |
|
23
Pulmonx
LUNG
$92.8M
| $203K | 0.02% |
+5,639
| New | +$222K |
|
24
Senseonics Holdings Inc
SENS
$409M
| $185K | 0.02% |
+2,731
| New | +$185K |
|
25
CalciMedica
CALC
$20.2M
| $164K | 0.01% |
+3,539
| New | +$199K |
|
Similar funds
HP
ACM
AGA
IAM
UM
RIM
BCM
AI
Johnson & Johnson's Q3 2021 Portfolio in Review
Q3 2021 is the first quarter with a 13F filing on record for Johnson & Johnson, which disclosed 25 positions worth $1.14B. Its ten largest holdings account for 95% of the portfolio.
Its largest position is Illumina: 832,855 shares worth $329M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, followed by Technology.
- Johnson & Johnson's largest Q3 2021 buy was Illumina: 832,855 shares worth $329M.
- Johnson & Johnson's ten largest holdings make up 95% of its $1.14B portfolio in Q3 2021.
- Johnson & Johnson disclosed 25 positions in Q3 2021, its first 13F filing on record.
Based on Johnson & Johnson's 13F filing for Q3 2021, filed 12 Nov 2021.